DR. PENG(SH:600804)2021-10-28 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥1,218,718,425.83, representing a decrease of 5.61% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2021 was ¥64,427,837.70, down 95.36% year-over-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥13,923,854.61, a decrease of 34.42% compared to the same period last year[7]. - The basic earnings per share for Q3 2021 was ¥0.05, reflecting a decline of 95.24% year-over-year[10]. - The diluted earnings per share for Q3 2021 was also ¥0.05, down 95.24% compared to the previous year[10]. - The weighted average return on equity for Q3 2021 was 3.32%, a decrease of 66.93 percentage points year-over-year[10]. - Total operating revenue for the first three quarters of 2021 was CNY 3,361,874,476.81, a decrease from CNY 4,141,970,350.96 in the same period of 2020, representing a decline of approximately 18.8%[38]. - Net profit for the third quarter of 2021 was CNY 1,063,409,088.73, down from CNY 1,716,070,343.09 in the same quarter of 2020, reflecting a decline of approximately 38.0%[41]. - The total comprehensive income for the period attributable to the parent company was CNY 1,069,368,482.31, a decrease from CNY 1,730,492,508.92 in the same period last year, representing a decline of approximately 38.1%[43]. - Basic and diluted earnings per share were both CNY 0.77, down from CNY 1.23 in the previous year, indicating a decrease of 37.4%[43]. Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥11,324,533,802.14, a decrease of 4.31% from the end of the previous year[10]. - Total liabilities increased to ¥5,000,000,000.00 from ¥4,500,000,000.00 year-over-year, an increase of approximately 11.1%[32]. - The company reported a total liability of CNY 9,276,769,323.39 as of the end of the reporting period, down from CNY 10,856,479,785.65 in the previous year, a reduction of about 14.5%[34]. - The total liabilities and equity amounted to CNY 11,324,533,802.14, a decrease from CNY 11,834,905,970.27 in the previous year, reflecting a decline of approximately 4.3%[34]. - Current liabilities reached approximately 7.59 billion, with short-term borrowings at about 1.31 billion[54]. - Total liabilities were approximately 10.86 billion, with non-current liabilities accounting for about 3.27 billion[54]. Shareholder Information - Total number of common stock shareholders at the end of the reporting period was 132,612[22]. - The largest shareholder, Shenzhen Pengbo Industrial Group Co., Ltd., holds 115,035,640 shares, accounting for 8.03% of total shares[24]. - The equity attributable to shareholders increased by 118.79% year-to-date, reaching ¥1,969,995,590.20[10]. - The total equity attributable to shareholders of the parent company increased to CNY 1,969,995,590.20 from CNY 900,393,834.59, marking an increase of approximately 118.8%[34]. Cash Flow and Investments - The company reported a decrease in cash inflow from investment activities, totaling CNY 3,032,897,001.22, compared to CNY 5,903,787,289.97 in the previous year, indicating a decline of approximately 48.7%[47]. - Cash flow from operating activities generated a net amount of CNY 196,576,543.13, compared to CNY 251,206,400.42 in the same period last year, reflecting a decline of about 21.7%[47]. - The net cash flow from investing activities was negative CNY 25,091,545.46, contrasting with a positive CNY 2,384,954,584.67 in the same period last year[47]. - The cash flow from financing activities resulted in a net outflow of CNY 145,596,097.19, compared to a net outflow of CNY 2,273,506,530.43 in the same period last year[47]. Operational Metrics - The company reported a significant decrease in net profit primarily due to lower investment income from subsidiaries compared to the same period last year[17]. - Research and development expenses for the first three quarters of 2021 were CNY 77,937,517.61, down from CNY 148,331,329.03 in the same period of 2020, a decrease of about 47.4%[38]. - The company’s financial expenses for the first three quarters of 2021 were CNY 258,011,317.08, compared to CNY 219,599,377.34 in 2020, indicating an increase of approximately 17.4%[38]. - The company has plans for market expansion and new product development, although specific figures were not disclosed in the report[24]. Inventory and Receivables - Accounts receivable increased to ¥576,151,519.27 from ¥431,250,224.62 year-over-year, representing a growth of approximately 33.7%[28]. - Prepayments rose significantly to ¥749,082,807.06 from ¥406,995,825.75 year-over-year, an increase of about 83.9%[28]. - The company reported a significant increase in inventory to ¥18,521,257.31 from ¥14,631,483.22 year-over-year, a growth of about 26.0%[28]. Cash and Cash Equivalents - The company's cash and cash equivalents decreased to ¥339,340,702.39 from ¥1,113,191,123.11 year-over-year[28]. - Total cash and cash equivalents at the end of the period amounted to CNY 269,340,702.39, down from CNY 1,100,814,699.32 at the end of the previous year[49]. - The impact of exchange rate changes on cash and cash equivalents was a decrease of CNY 9,449,721.20, compared to a decrease of CNY 13,691,546.29 in the previous year[49].